{"id":3257,"date":"2025-03-18T14:46:15","date_gmt":"2025-03-18T11:46:15","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3257"},"modified":"2025-11-03T20:25:21","modified_gmt":"2025-11-03T17:25:21","slug":"biophytis-bio101-therapy-for-sarcopenia-could-bring-hope-to-duchenne-muscular-dystrophy-patients","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/biophytis-bio101-therapy-for-sarcopenia-could-bring-hope-to-duchenne-muscular-dystrophy-patients\/","title":{"rendered":"La th\u00e9rapie Biophytis&#039; BIO101 pour le traitement de la sarcop\u00e9nie pourrait apporter de l&#039;espoir aux patients atteints de dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">L&#039;essai clinique de phase 2 SARA-INT a \u00e9t\u00e9 publi\u00e9 dans le Journal of Cachexia, Sarcopenia and Muscle (JCSM), la principale revue de r\u00e9f\u00e9rence pour la recherche sur la sarcop\u00e9nie, marquant une premi\u00e8re mondiale pour Biophytis, une soci\u00e9t\u00e9 de biotechnologie au stade clinique sp\u00e9cialis\u00e9e dans la cr\u00e9ation de traitements pour les maladies li\u00e9es \u00e0 l&#039;\u00e2ge.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Les principaux attributs BIO101 du sentier SARA INT comprennent\u00a0:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacit\u00e9 prometteuse :<\/strong> BIO101 350 mg bid d\u00e9montre une am\u00e9lioration cliniquement significative du test de marche de 400 m\u00e8tres (400MWT), crit\u00e8re d&#039;\u00e9valuation principal de l&#039;\u00e9tude<\/li>\n\n\n\n<li><strong>Excellente s\u00e9curit\u00e9 :<\/strong> \u00c0 toutes les doses, BIO101 pr\u00e9sente un tr\u00e8s bon profil de s\u00e9curit\u00e9 sans aucun \u00e9v\u00e9nement ind\u00e9sirable grave (EI) li\u00e9 au produit.<\/li>\n\n\n\n<li><strong>Efficacit\u00e9 accrue dans la population \u00e0 haut risque :<\/strong> Effet du traitement nominalement significatif par rapport au placebo sur la vitesse de marche au 400MWT chez les marcheurs lents et les sous-populations ob\u00e8ses sarcop\u00e9niques<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">\u00c0 propos de BIOPHYTIS<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Entreprise de biotechnologie en phase clinique, Biophytis SA se consacre au d\u00e9veloppement de candidats m\u00e9dicaments pour les maladies li\u00e9es \u00e0 l&#039;\u00e2ge. Son principal candidat m\u00e9dicament, le BIO101 (20-hydroxyecdysone), est une petite mol\u00e9cule en cours de d\u00e9veloppement pour les maladies respiratoires (COVID-19, phase 2-3 termin\u00e9e), les troubles m\u00e9taboliques (ob\u00e9sit\u00e9, phase 2 en cours de d\u00e9marrage) et les maladies musculaires (sarcop\u00e9nie, phase 3 pr\u00eate \u00e0 d\u00e9marrer, et myopathie de Duchenne, phases 1-2 en cours de d\u00e9marrage).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The Phase 2 clinical trial SARA-INT was published in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the primary reference journal for sarcopenia research, marking a world premiere for Biophytis, a clinical-stage biotechnology company that specializes in creating treatments for age-related diseases. Key BIO101 Attributes from the SARA INT Trail include: About BIOPHYTIS A clinical-stage [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3259,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[309,308,307,66,310],"class_list":["post-3257","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-bio101","tag-bio101-therapy","tag-biophytis","tag-duchenne-muscular-dystrophy","tag-sarcopenia"],"subtitle":"Biophytis a le plaisir d'annoncer la publication de l'essai clinique de phase 2 SARA-INT dans le magazine Cachexia, Sarcopenia, and Muscle (JCSM), le principal magazine de recherche sur la sarcop\u00e9nie.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3257"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3259"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}